Rapid Detection of Mycobacterium tuberculosis and Rifampin Resistance by Use of On-Demand, Near-Patient Technology
Open accessThe DOI matches its Crossref record; 58 of the 59 references it cites were found in a registry or an index.
Abstract
Current nucleic acid amplification methods to detect Mycobacterium tuberculosis are complex, labor-intensive, and technically challenging. We developed and performed the first analysis of the Cepheid Gene Xpert System's MTB/RIF assay, an integrated hands-free sputum-processing and real-time PCR system with rapid on-demand, near-patient technology, to simultaneously detect M. tuberculosis and rifampin resistance. Analytic tests of M. tuberculosis DNA demonstrated a limit of detection (LOD) of 4.5 genomes per reaction. Studies using sputum spiked with known numbers of M. tuberculosis CFU predicted a clinical LOD of 131 CFU/ml. Killing studies showed that the assay's buffer decreased M. tuberculosis viability by at least 8 logs, substantially reducing biohazards. Tests of 23 different commonly occurring rifampin resistance mutations demonstrated that all 23 (100%) would be identified as rifampin resistant. An analysis of 20 nontuberculosis mycobacteria species confirmed high assay specificity. A small clinical validation study of 107 clinical sputum samples from suspected tuberculosis cases in Vietnam detected 29/29 (100%) smear-positive culture-positive cases and 33/39 (84.6%) or 38/53 (71.7%) smear-negative culture-positive cases, as determined by growth on solid medium or on both solid and liquid media, respectively. M. tuberculosis was not detected in 25/25 (100%) of the culture-negative samples. A study of 64 smear-positive culture-positive sputa from retreatment tuberculosis cases in Uganda detected 63/64 (98.4%) culture-positive cases and 9/9 (100%) cases of rifampin resistance. Rifampin resistance was excluded in 54/55 (98.2%) susceptible cases. Specificity rose to 100% after correcting for a conventional susceptibility test error. In conclusion, this highly sensitive and simple-to-use system can detect M. tuberculosis directly from sputum in less than 2 h.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies have shown that Xpert does not cross‐react with other mycobacterial species (Blakemore 2010; Helb 2010).”
From Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults (2021) · cites this paper as Helb 2010
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This represents a substantial reduction in diagnostic delay, thereby permitting real-time decision making and planning of treatment (5).”
From Xpert MTB/RIF for Rapid Diagnosis of Tuberculous Lymphadenitis from Fine-Needle-Aspiration Biopsy Specimens (2011) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“Previous studies reported 98–100% agreement in detection of rifampicin resistance strains using the Xpert test and phenotypic drug susceptibility test [13,14,18,26].”
From GeneXpert MTB/RIF Assay for the Diagnosis of Tuberculous Lymphadenitis on Concentrated Fine Needle Aspirates in High Tuberculosis Burden Settings (2015) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“Such cases (Xpert-positive but culture-negative) are likely to be true TB positives as corroborated by the high specificity [14,18] and by the fact that the procedure is less prone to contamination due to the closed reaction chamber (real-time PCR technology) of Xpert.”
From GeneXpert MTB/RIF Assay for the Diagnosis of Tuberculous Lymphadenitis on Concentrated Fine Needle Aspirates in High Tuberculosis Burden Settings (2015) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“In agreement with other studies [9,18,22], Xpert has a higher sensitivity than smear microscopy.”
From GeneXpert MTB/RIF Assay for the Diagnosis of Tuberculous Lymphadenitis on Concentrated Fine Needle Aspirates in High Tuberculosis Burden Settings (2015) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Griffith, D. E., Aksamit, T., Brown-Elliott, B. A., Catanzaro, A., Daley, C., Gordin, F., Holland, S. M., Horsburgh, R., Huitt, G., Iademarco, M. F., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200604-571st · Cited by 6,110
Two-sided confidence intervals for the single proportion: comparison of seven methods
Newcombe, R. G. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19980430)17:8<857::aid-sim777>3.0.co;2-e · Cited by 5,107
Probable Inference, the Law of Succession, and Statistical Inference
Wilson, E. B. (1927) · Journal of the American Statistical Association · doi:10.1080/01621459.1927.10502953 · Cited by 4,476
Sexually transmitted diseases treatment guidelines
Burstein, G. R., & Workowski, K. A. (2003) · Current Opinion in Pediatrics · doi:10.1097/00008480-200308000-00006 · Cited by 2,072
Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines
Workowski, K. A., & Berman, S. M. (2007) · Clinical Infectious Diseases · doi:10.1086/511430 · Cited by 1,973
The association for the advancement of medical instrumentation
(1974) · Ultrasound in Medicine & Biology · doi:10.1016/0301-5629(74)90035-0 · Cited by 1,031
Anti-tuberculosis drug resistance in the world
Wilkinson, D. (1998) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(98)90766-0 · Cited by 700
Molecular Detection of Antimicrobial Resistance
Fluit, A. C., Visser, M. R., & Schmitz, F.-J. (2001) · Clinical Microbiology Reviews · doi:10.1128/cmr.14.4.836-871.2001 · Cited by 525 · cited 1×
“tuberculosis detection (15), this assay was too complex and too prone to operator errors, sample cross-contamination, and biohazards for rapid near-patient use.”
BackgroundEspinal, M. A., Kim, S. J., Suarez, P. G., Kam, K. M., Khomenko, A. G., Migliori, G. B., Baéz, J., Kochi, A., Dye, C., & Raviglione, M. C. (2000) · JAMA · doi:10.1001/jama.283.19.2537 · Cited by 507 · cited 3×
“Truly rapid results for drug susceptibility tests are particularly important in the management of drug-resistant tuberculosis (13).”
BackgroundMicroscopic-Observation Drug-Susceptibility Assay for the Diagnosis of TB
Moore, D. A. J., Evans, C. A. W., Gilman, R. H., Caviedes, L., Coronel, J., Vivar, A., Sanchez, E., Piñedo, Y., Saravia, J. C., Salazar, C., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055524 · Cited by 468
Cited by
Rapid Molecular Detection of Tuberculosis and Rifampin Resistance
Boehme, C. C., Nabeta, P., Hillemann, D., Nicol, M. P., Shenai, S., Krapp, F., Allen, J., Tahirli, R., Blakemore, R., Rustomjee, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907847 · Cited by 2,309
Self-citationXpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults
Steingart, K. R., Schiller, I., Horne, D. J., Pai, M., Boehme, C. C., & Dendukuri, N. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009593.pub3 · Cited by 1,102
Self-citationBoehme, C. C., Nicol, M. P., Nabeta, P., Michael, J. S., Gotuzzo, E., Tahirli, R., Gler, M. T., Blakemore, R., Worodria, W., Gray, C., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60438-8 · Cited by 1,013
Self-citationLewinsohn, D. M., Leonard, M. K., LoBue, P. A., Cohn, D. L., Daley, C. L., Desmond, E., Keane, J., Lewinsohn, D. A., Loeffler, A. M., Mazurek, G. H., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw694 · Cited by 992
“These assays are promising, but are not yet commercially available [146, 159, 160].”
BackgroundTuberculous meningitis: a uniform case definition for use in clinical research
Marais, S., Thwaites, G., Schoeman, J. F., Török, M. E., Misra, U. K., Prasad, K., Donald, P. R., Wilkinson, R. J., & Marais, B. J. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70138-9 · Cited by 932
Point-of-care nucleic acid testing for infectious diseases
Niemz, A., Ferguson, T. M., & Boyle, D. S. (2011) · Trends in Biotechnology · doi:10.1016/j.tibtech.2011.01.007 · Cited by 838
Lawn, S. D., & Zumla, A. I. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62173-3 · Cited by 751
Chakravorty, S., Simmons, A. M., Rowneki, M., Parmar, H., Cao, Y., Ryan, J., Banada, P. P., Deshpande, S., Shenai, S., Gall, A., et al. (2017) · mBio · doi:10.1128/mbio.00812-17 · Cited by 668
“tuberculosis directly from sputum, with a limit of detection (LOD) of 131 CFU/ml (1).”
BackgroundMethodInfluentialSelf-citationLaboratory Diagnosis of Tuberculosis in Resource-Poor Countries: Challenges and Opportunities
Parsons, L. M., Somoskövi, Á., Gutierrez, C., Lee, E., Paramasivan, C. N., Abimiku, A., Spector, S., Roscigno, G., & Nkengasong, J. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00059-10 · Cited by 540
“7% for smear-negative and solid-plus-liquid-culture-positive specimens (64).”
Point-of-Care Diagnostics: Recent Developments in a Connected Age
Nayak, S., Blumenfeld, N. R., Laksanasopin, T., & Sia, S. K. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.6b04630 · Cited by 508
Lawn, S. D., & Nicol, M. P. (2011) · Future Microbiology · doi:10.2217/fmb.11.84 · Cited by 486
“Mycobacterium tuberculosis is detected by the five overlapping molecular probes (probes A–E) that collectively are complementary to the entire 81 bp rpoB core region [8,9].”
BackgroundMethodInfluentialEvaluation of the analytical performance of the Xpert MTB/RIF assay
Blakemore, R., Story, E., Helb, D., Kop, J., Banada, P., Owens, M. R., Chakravorty, S., Jones, M., & Alland, D. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.00128-10 · Cited by 485
“have recently been described in detail (7).”
BackgroundMethodInfluentialSelf-citationLawn, S. D., Mwaba, P., Bates, M., Piatek, A., Alexander, H., Marais, B. J., Cuevas, L. E., McHugh, T. D., Zijenah, L., Kapata, N., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70008-2 · Cited by 458
“22,23 Further experiments were done in which DNA from resistant and susceptible strains were mixed in varying ratios to assess how this affected detection of rifampicin resistance.”
BackgroundMethodInfluentialFord, C. B., Shah, R. R., Maeda, M. K., Gagneux, S., Murray, M. B., Cohen, T., Johnston, J. C., Gardy, J., Lipsitch, M., & Fortune, S. M. (2013) · Nature Genetics · doi:10.1038/ng.2656 · Cited by 457
“Smear microscopy is the most common primary diagnostic for M. tuberculosis around the world but is orders of magnitude less sensitive than both culture and molecular diagnostics 67,68 .”
Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice
Wallis, R. S., Pai, M., Menzies, D., Doherty, T. M., Walzl, G., Perkins, M. D., & Zumla, A. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60359-5 · Cited by 453
Self-citationAdvances and challenges in biosensor-based diagnosis of infectious diseases
Sin, M. L., Mach, K. E., Wong, P. K., & Liao, J. C. (2014) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2014.888313 · Cited by 435
Whole genome sequencing of Mycobacterium tuberculosis: current standards and open issues
Meehan, C. J., Goig, G. A., Kohl, T. A., Verboven, L., Dippenaar, A., Ezewudo, M., Farhat, M. R., Guthrie, J. L., Laukens, K., Miotto, P., et al. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0214-5 · Cited by 422
Rapid Molecular Detection of Extrapulmonary Tuberculosis by the Automated GeneXpert MTB/RIF System
Hillemann, D., Rüsch-Gerdes, S., Boehme, C., & Richter, E. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.02268-10 · Cited by 413
“The Xpert assay was performed as recently described (11).”
MethodSelf-citationZeka, A. N., Tasbakan, S., & Cavusoglu, C. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.05434-11 · Cited by 362
“A previous study found that the MTB/RIF assay had a calculated limit of detection of 131 CFU/ml of sputum and was able to detect as few as 10 CFU/ml of sputum in 35% of samples (9).”
BackgroundMethodInfluentialXpert MTB/RIF: a New Pillar in Diagnosis of Extrapulmonary Tuberculosis?
Vadwai, V., Boehme, C., Nabeta, P., Shetty, A., Alland, D., & Rodrigues, C. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.02319-10 · Cited by 357
“), based on nested real-time PCR and molecular beacon technology, has been shown to be rapid, with a result for TB and RIF resistance in under 2 h (12); is not prone to cross-contamination; requires minimal biosafety facilities (4); can be performed by technicians with little training; and has a high sensitivity in sm…”
BackgroundSelf-citationSelf-powered integrated microfluidic point-of-care low-cost enabling (SIMPLE) chip
Yeh, E.-C., Fu, C.-C., Hu, L., Thakur, R., Feng, J., & Lee, L. P. (2017) · Science Advances · doi:10.1126/sciadv.1501645 · Cited by 347
Nicol, M. P., Workman, L., Isaacs, W., Munro, J., Black, F., Eley, B., Boehme, C. C., Zemanay, W., & Zar, H. J. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70167-0 · Cited by 338
Self-citationClinical validation of Xpert MTB/RIF for the diagnosis of extrapulmonary tuberculosis
Tortoli, E., Russo, C., Piersimoni, C., Mazzola, E., Dal Monte, P., Pascarella, M., Borroni, E., Mondo, A., Piana, F., Scarparo, C., et al. (2012) · European Respiratory Journal · doi:10.1183/09031936.00176311 · Cited by 322
“There is a large number of studies evaluating Xpert on pulmonary specimens [5,6,17-23]; the sensibility varies from 95 to 100% in smear-positive sputa, and from 47 to 77% in smearnegative ones.”
BackgroundDetjen, A. K., DiNardo, A. R., Leyden, J., Steingart, K. R., Menzies, D., Schiller, I., Dendukuri, N., & Mandalakas, A. M. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00095-8 · Cited by 319
Immunology of Mycobacterium tuberculosis Infections
Sia, J. K., & Rengarajan, J. (2019) · Microbiology Spectrum · doi:10.1128/microbiolspec.gpp3-0022-2018 · Cited by 312
Practical Guidance for Clinical Microbiology Laboratories: Mycobacteria
Forbes, B. A., Hall, G. S., Miller, M. B., Novak, S. M., Rowlinson, M.-C., Salfinger, M., Somoskövi, A., Warshauer, D. M., & Wilson, M. L. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00038-17 · Cited by 311
Theron, G., Peter, J., van Zyl-Smit, R., Mishra, H., Streicher, E., Murray, S., Dawson, R., Whitelaw, A., Hoelscher, M., Sharma, S., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201101-0056oc · Cited by 311
Bahr, N. C., Nuwagira, E., Evans, E. E., Cresswell, F. V., Bystrom, P. V., Byamukama, A., Bridge, S. C., Bangdiwala, A. S., Meya, D. B., Denkinger, C. M., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30474-7 · Cited by 308
Acharya, B., Acharya, A., Gautam, S., Ghimire, S. P., Mishra, G., Parajuli, N., & Sapkota, B. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05413-7 · Cited by 292
“This “laboratory in cartridge” [48] is simple to perform with lower biohazard risk, robust, has a rapid turnaround time (90 min) [48, 49] and promising performance with a sensitivity of 98% to detect rifampicin resistance [50] and the presence of tubercle bacilli in smear positive cases and 70% for smear negative samp…”
BackgroundLawn, S. D., Brooks, S. V., Kranzer, K., Nicol, M. P., Whitelaw, A., Vogt, M., Bekker, L.-G., & Wood, R. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1001067 · Cited by 278
“Sputum pellets were also tested by trained technologists using the Xpert MTB/RIF assay as previously described [20,22,23].”
BackgroundMethodInfluentialPoint of care testing for infectious diseases
Chen, H., Liu, K., Li, Z., & Wang, P. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.03.008 · Cited by 270
Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults
Horne, D. J., Kohli, M., Zifodya, J. S., Schiller, I., Dendukuri, N., Tollefson, D., Schumacher, S. G., Ochodo, E. A., Pai, M., & Steingart, K. R. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009593.pub4 · Cited by 267
“%) to have unclear risk of bias because we could not tell if all participants were included in the analysis (Chaisson 2014; Dorman 2018; Hanrahan 2014; Helb 2010; Rachow 2011; Tsuyuguchi 2017).”
BackgroundMethodInfluentialChang, K., Lu, W., Wang, J., Zhang, K., Jia, S., Li, F., Deng, S., & Chen, M. (2012) · Journal of Infection · doi:10.1016/j.jinf.2012.02.012 · Cited by 267
Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF
Weyer, K., Mirzayev, F., Migliori, G. B., Van Gemert, W., D'Ambrosio, L., Zignol, M., Floyd, K., Centis, R., Cirillo, D. M., Tortoli, E., et al. (2013) · European Respiratory Journal · doi:10.1183/09031936.00157212 · Cited by 256
Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults
Steingart, K. R., Sohn, H., Schiller, I., Kloda, L. A., Boehme, C. C., Pai, M., & Dendukuri, N. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009593.pub2 · Cited by 253
Self-citationMarlowe, E. M., Novak-Weekley, S. M., Cumpio, J., Sharp, S. E., Momeny, M. A., Babst, A., Carlson, J. S., Kawamura, M., & Pandori, M. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.02214-10 · Cited by 253
“Our results are consistent with those reported by others (4, 5, 10).”
BackgroundMethodResultInfluentialXpert ® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance
Kohli, M., Schiller, I., Dendukuri, N., Dheda, K., Denkinger, C. M., Schumacher, S. G., & Steingart, K. R. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012768.pub2 · Cited by 245
Menzies, N. A., Cohen, T., Lin, H.-H., Murray, M., & Salomon, J. A. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001347 · Cited by 222
“Within 10 y after the introduction of Xpert, prevalence would be lower by 186 (95% CI: 86–350) per 100,000 (28% [95% CI: 14–40]), incidence by 35 (13–79) per 100,000 (6% [2–13]), and annual TB mortality by 50 (23–89) per 100,000 (21% [10–32]), compared to status quo projections.”
MethodMaynard-Smith, L., Larke, N., Peters, J. A., & Lawn, S. D. (2014) · BMC Infectious Diseases · doi:10.1186/s12879-014-0709-7 · Cited by 218
Kohli, M., Schiller, I., Dendukuri, N., Yao, M., Dheda, K., Denkinger, C. M., Schumacher, S. G., & Steingart, K. R. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012768.pub3 · Cited by 215
Ngabonziza, J. C. S., Loiseau, C., Marceau, M., Jouet, A., Menardo, F., Tzfadia, O., Antoine, R., Niyigena, E. B., Mulders, W., Fissette, K., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16626-6 · Cited by 214
Towards a point-of-care test for active tuberculosis: obstacles and opportunities
McNerney, R., & Daley, P. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2521 · Cited by 208
Tuberculosis Diagnostics and Biomarkers: Needs, Challenges, Recent Advances, and Opportunities
McNerney, R., Maeurer, M., Abubakar, I., Marais, B., Mchugh, T. D., Ford, N., Weyer, K., Lawn, S., Grobusch, M. P., Memish, Z., et al. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir860 · Cited by 191
“Assay sensitivity is higher than that of smear microscopy and close to that of culture [47–54].”
BackgroundMethodFriedrich, S. O., Rachow, A., Saathoff, E., Singh, K., Mangu, C. D., Dawson, R., Phillips, P. P., Venter, A., Bateson, A., Boehme, C. C., et al. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70119-x · Cited by 181
Self-citationArmand, S., Vanhuls, P., Delcroix, G., Courcol, R., & Lemaître, N. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.02157-10 · Cited by 179
“Moreover, the similar sensitivities of the Xpert MTB/RIF test with fresh and frozen specimens were reported in analytic studies (9).”
BackgroundMethodResultInfluentialPatel, V. B., Theron, G., Lenders, L., Matinyena, B., Connolly, C., Singh, R., Coovadia, Y., Ndung'u, T., & Dheda, K. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001536 · Cited by 179
“The Xpert MTB/RIF assay consists of two main components, namely, a Xpert MTB/RIF plastic cartridge (containing the liquid sample processing and PCR buffers, and lyophilized real-time PCR reagents with internal sample processing and PCR probe quality controls) and the automated Xpert MTB/RIF machine (which controls the…”
MethodZifodya, J. S., Kreniske, J. S., Schiller, I., Kohli, M., Dendukuri, N., Schumacher, S. G., Ochodo, E. A., Haraka, F., Zwerling, A. A., Pai, M., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009593.pub5 · Cited by 179
Govindarajan, A. V., Ramachandran, S., Vigil, G. D., Yager, P., & Böhringer, K. F. (2012) · Lab Chip · doi:10.1039/c1lc20622b · Cited by 177
Zumla, A., Al-Tawfiq, J. A., Enne, V. I., Kidd, M., Drosten, C., Breuer, J., Muller, M. A., Hui, D., Maeurer, M., Bates, M., et al. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70827-8 · Cited by 175
“[130] [131] [132] [133] [134] [135] [136] [137] [138] [139] There is a need to improve our understanding of the role of individual microorganisms in respiratory disease and the true relationship between pathogen quantity and disease.”
BackgroundGeneXpert—A Game-Changer for Tuberculosis Control?
Evans, C. A. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1001064 · Cited by 172
“The MTB/RIF test offers a potential solution for improving TB diagnosis”
MethodZhao, Y., Zuo, X., Li, Q., Chen, F., Chen, Y.-R., Deng, J., Han, D., Hao, C., Huang, F., Huang, Y., et al. (2020) · Science China Chemistry · doi:10.1007/s11426-020-9864-7 · Cited by 178
Thomas, T. A. (2017) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2017.03.010 · Cited by 202
Moure, R., Muñoz, L., Torres, M., Santin, M., Martín, R., & Alcaide, F. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.01831-10 · Cited by 165
“A real-time automated integrated system, the GeneXpert system using the Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA) (GX), has recently been developed and evaluated (2, 3, 10).”
MethodCohen, K. A., Manson, A. L., Desjardins, C. A., Abeel, T., & Earl, A. M. (2019) · Genome Medicine · doi:10.1186/s13073-019-0660-8 · Cited by 163
“However, the targeted amplification and sequencing of known or suspected resistance genes revealed that these mechanisms were insufficient to explain all phenotypic resistance [85, 86], and resistance mechanisms for several newer drugs—including pretomanid, bedaquiline, and delamanid—were discovered over the next eigh…”
BackgroundRachow, A., Zumla, A., Heinrich, N., Rojas-Ponce, G., Mtafya, B., Reither, K., Ntinginya, E. N., O'Grady, J., Huggett, J., Dheda, K., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020458 · Cited by 160
“Frozen sputa were thawed and processed according to the Xpert MTB/RIF Assay test procedure [9].”
BackgroundMethodInfluentialSelf-citationYin, Y., Zhu, P., Guo, Y., Li, Y., Chen, H., Liu, J., Sun, L., Ma, S., Hu, C., & Wang, H. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105307 · Cited by 160
“In initial analytical studies, in which a LoD of 131 CFU/mL, with which Xpert-MTB detected M. tuberculosis in sputum, 30 could help to explain this.”
Rie, A. V., Page-Shipp, L., Scott, L., Sanne, I., & Stevens, W. (2010) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.67 · Cited by 159
New specimens and laboratory diagnostics for childhood pulmonary TB: progress and prospects
Nicol, M. P., & Zar, H. J. (2011) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2010.09.008 · Cited by 158
Banada, P. P., Sivasubramani, S. K., Blakemore, R., Boehme, C., Perkins, M. D., Fennelly, K., & Alland, D. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.01053-10 · Cited by 149
“tuberculosis in sputum by at least 6 log10 units after 15 min of incubation (14).”
BackgroundInfluentialSelf-citationPoint‐of‐care diagnosis of tuberculosis: Past, present and future
Dheda, K. U. J., Rühwald, M., Theron, G., Peter, J., & Yam, W. C. (2012) · Respirology · doi:10.1111/resp.12022 · Cited by 172
Rachow, A., Clowes, P., Saathoff, E., Mtafya, B., Michael, E., Ntinginya, E. N., Kowour, D., Rojas-Ponce, G., Kroidl, A., Maboko, L., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis190 · Cited by 147
“All sputum samples tested by Xpert assay were processed according to the manufacturer’s instructions [19].”
MethodCox, H. S., Mbhele, S., Mohess, N., Whitelaw, A., Muller, O., Zemanay, W., Little, F., Azevedo, V., Simpson, J., Boehme, C. C., et al. (2014) · PLoS Medicine · doi:10.1371/journal.pmed.1001760 · Cited by 145
“The Xpert MTB/RIF test is a real-time PCR assay for simultaneous detection of Mycobacterium tuberculosis and rifampicin resistance [3].”
MethodSelf-citationLaboratory Diagnosis of Mycobacterium tuberculosis Infection and Disease in Children
Dunn, J. J., Starke, J. R., & Revell, P. A. (2016) · Journal of Clinical Microbiology · doi:10.1128/jcm.03043-15 · Cited by 153
“Initial analytical studies showed that the limit of detection of the Xpert MTB/RIF assay was 131 CFU/ml of sputum (31).”
MethodIoannidis, P., Papaventsis, D., Karabela, S., Nikolaou, S., Panagi, M., Raftopoulou, E., Konstantinidou, E., Marinou, I., & Kanavaki, S. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.00718-11 · Cited by 153
“The recently introduced Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA) detects the presence of MTBC DNA and its susceptibility to rifampin (RMP) in a single reaction (4, 8).”
MethodTuberculosis Diagnostics: State of the Art and Future Directions
Pai, M., Nicol, M. P., & Boehme, C. C. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.tbtb2-0019-2016 · Cited by 164
Self-citationKay, A. W., Fernández, L. G., Takwoingi, Y., Eisenhut, M., Detjen, A., Steingart, K. R., & Mandalakas, A. M. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013359.pub2 · Cited by 154
Comparison of Two Molecular Methods for Rapid Diagnosis of Extrapulmonary Tuberculosis
Causse, M., Ruiz, P., Gutiérrez-Aroca, J. B., & Casal, M. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.00491-11 · Cited by 145
“Findings for specificity (98%) were also similar to those reported by other authors (2, 3, 10).”
ResultTrichomonas vaginalis : Clinical relevance, pathogenicity and diagnosis
Edwards, T., Burke, P., Smalley, H., & Hobbs, G. (2014) · Critical Reviews in Microbiology · doi:10.3109/1040841x.2014.958050 · Cited by 205
“The GeneXpert is a platform for processing real-time PCR based assays with fully automated sample preparation, amplification and detection on disposable assay-specific cartridges, providing results within 90 min to enable sameday testing and treatment (Helb et al., 2010).”
Zetola, N. M., Shin, S. S., Tumedi, K. A., Moeti, K., Ncube, R., Nicol, M., Collman, R. G., Klausner, J. D., & Modongo, C. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.02489-13 · Cited by 140
Vandeventer, P. E., Weigel, K. M., Salazar, J., Erwin, B., Irvine, B. D., Doebler, R. W., Nadim, A., Cangelosi, G. A., & Niemz, A. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.02171-10 · Cited by 139
“tuberculosis (7, 16), and Clostridium difficile (26), three pathogens that are known to be lysis resistant.”
BackgroundBassett, I. V., Wang, B., Chetty, S., Giddy, J., Losina, E., Mazibuko, M., Bearnot, B. I., Allen, J., Walensky, R. P., & Freedberg, K. A. (2010) · Clinical Infectious Diseases · doi:10.1086/656282 · Cited by 139
“ing and has shown promising results in a small study [30].”
Point of care diagnostics for tuberculosis
García‐Basteiro, A. L., DiNardo, A. R., Saavedra, B., Silva, D. R., Palmero, D., Gegia, M., Migliori, G. B., Duarte, R., Mambuque, E., Centis, R., et al. (2018) · Pulmonology · doi:10.1016/j.rppnen.2017.12.002 · Cited by 152
“Xpert is a real-time quantitative PCR assay for Mycobacterium tuberculosis-complex DNA.(18) It amplifies part of the rpoB gene that contains mutations that cause rifampicinresistance (a critical first-line drug).”
Integrated microfluidic systems with sample preparation and nucleic acid amplification
Yin, J., Suo, Y., Zou, Z., Sun, J., Zhang, S., Wang, B., Xu, Y., Darland, D. C., Zhao, J. X., & Mu, Y. (2019) · Lab on a Chip · doi:10.1039/c9lc00389d · Cited by 138
Doughty, E. L., Sergeant, M. J., Adetifa, I., Antonio, M., & Pallen, M. J. (2014) · PeerJ · doi:10.7717/peerj.585 · Cited by 132
Theron, G., Peter, J., Calligaro, G., Meldau, R., Hanrahan, C., Khalfey, H., Matinyenya, B., Muchinga, T., Smith, L., Pandie, S., et al. (2014) · Scientific Reports · doi:10.1038/srep05658 · Cited by 121
Xpert MTB/RIF Assay for Diagnosis of Pleural Tuberculosis
Friedrich, S. O., von Groote-Bidlingmaier, F., & Diacon, A. H. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.05454-11 · Cited by 126
“tuberculosis complex DNA, as well as rpoB gene mutations conferring rifampin resistance, rapidly and with high accuracy (1, 2, 7).”
BackgroundComparison of Quantitative Techniques including Xpert MTB/RIF to Evaluate Mycobacterial Burden
van Zyl-Smit, R. N., Binder, A. B., Meldau, R., Mishra, H. K., Semple, P. L., Theron, G., Peter, J., Whitelaw, A. C., Sharma, S. K., Warren, R. M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028815 · Cited by 126
“Most notably, apart from the semi automation of the methods, DNA from degraded organisms is thought to be removed in the wash step and only intact organisms are retained in the cartridge mesh for the PCR step [19].”
MethodClinical use of whole genome sequencing for Mycobacterium tuberculosis
Witney, A. A., Cosgrove, C. A., Arnold, A., Hinds, J., Stoker, N. G., & Butcher, P. D. (2016) · BMC Medicine · doi:10.1186/s12916-016-0598-2 · Cited by 134
“Following microscopy, an AFB smear-positive sputum is also tested for genetic markers of RIF resistance using the Xpert® MTB/RIF assay (Cepheid, Sunnyvale, CA, USA) [6]; results are available within two days.”
MethodLigthelm, L. J., Nicol, M. P., Hoek, K. G. P., Jacobson, R., van Helden, P. D., Marais, B. J., Warren, R. M., & Wright, C. A. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.01310-11 · Cited by 123
“This represents a substantial reduction in diagnostic delay, thereby permitting real-time decision making and planning of treatment (5).”
BackgroundA multisite assessment of the quantitative capabilities of the Xpert MTB/RIF assay
Blakemore, R., Nabeta, P., Davidow, A. L., Vadwai, V., Tahirli, R., Munsamy, V., Nicol, M., Jones, M., Persing, D. H., Hillemann, D., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201103-0536oc · Cited by 118
“tuberculosis and its susceptibility to the important first-line drug rifampin in less than 2 hours (7).”
BackgroundSelf-citationScott, L. E., Beylis, N., Nicol, M., Nkuna, G., Molapo, S., Berrie, L., Duse, A., & Stevens, W. S. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.03553-13 · Cited by 114
“This may be due to specimen collection, storage, and preparation techniques (8) or to reduced numbers (below the 131 CFU/ml threshold) (23, 24) of M.”
BackgroundImproved diagnostic sensitivity for tuberculous meningitis with Xpert® MTB/RIF of centrifuged CSF
Bahr, N. C., Tugume, L., Rajasingham, R., Kiggundu, R., Williams, D. A., Morawski, B., Alland, D., Meya, D. B., Rhein, J., & Boulware, D. R. (2015) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.15.0253 · Cited by 113
Self-citationWalusimbi, S., Bwanga, F., Costa, A. D., Haile, M., Joloba, M. L., & Hoffner, S. (2013) · BMC Infectious Diseases · doi:10.1186/1471-2334-13-507 · Cited by 114
“GeneXpert Helb, 2010 [24] Vietnam 1 Sputum frozen Unclear 38 0 15 25”
Lawn, S. D., & Wood, R. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir411 · Cited by 120
“Laboratory evaluations have shown a limit of detection (as defined by 95% sensitivity) of 131 bacilli per mL of sputum [70], whereas automated liquid culture systems have a sensitivity range of 10–100 organisms per mL.”
BackgroundMethodCao, Y., Parmar, H., Gaur, R. L., Lieu, D., Raghunath, S., Via, N., Battaglia, S., Cirillo, D. M., Denkinger, C. M., Georghiou, S. B., et al. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.02314-20 · Cited by 121
Self-citationTheron, G., Peter, J., Meldau, R., Khalfey, H., Gina, P., Matinyena, B., Lenders, L., Calligaro, G., Allwood, B., Symons, G., et al. (2013) · Thorax · doi:10.1136/thoraxjnl-2013-203485 · Cited by 122
“15 16 The laboratory technician performing the procedure was blinded to patient information and test results.”
MethodPantoja, A., Fitzpatrick, C., Vassall, A., Weyer, K., & Floyd, K. (2013) · European Respiratory Journal · doi:10.1183/09031936.00147912 · Cited by 105
Witney, A. A., Gould, K. A., Arnold, A., Coleman, D., Delgado, R., Dhillon, J., Pond, M. J., Pope, C. F., Planche, T., Stoker, N. G., et al. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.02993-14 · Cited by 117
“Molecular diagnostics have enabled the rapid identification of potential resistance-associated mutations; PCR-based methods, such as the GeneXpert MTB/RIF (Cepheid) (5) and GenoType MTBDRplus (Hain Lifescience) (6) assays, have become routine in many laboratories to identify MDR-TB strains by detecting the”
MethodXpert MTB/RIF Ultra assay for tuberculosis disease and rifampicin resistance in children
Kay, A. W., Ness, T. E., Verkuijl, S. E., Viney, K. A., Brands, A., Masini, T., Fernández, L. G., Eisenhut, M., Detjen, A., Mandalakas, A. M., et al. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013359.pub3 · Cited by 124
GeneXpert for TB diagnosis: planned and purposeful implementation
Piatek, A. S., van Cleeff, M. R. A., Alexander, H. L., Coggin, W. L., Rehr, M., van Kampen, S. C., Shinnick, T. M., & Mukadi, Y. (2013) · Global Health Science and Practice · doi:10.9745/ghsp-d-12-00004 · Cited by 105
“(RIF) resistance (a reliable proxy for MDR-TB) directly from sputum specimens in less than 2 hours, and it minimizes staff manipulation and biosafety risk.(4)”
BackgroundAlvarez-Uria, G., Azcona, J. M., Midde, M., Naik, P. K., Reddy, S., & Reddy, R. (2012) · Tuberculosis Research and Treatment · doi:10.1155/2012/932862 · Cited by 104
“Sample preparation and Xpert MTB/RIF procedure were performed by trained operators as described previously [12, 13].”
MethodPerez-Risco, D., Rodriguez-Temporal, D., Valledor-Sanchez, I., & Alcaide, F. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.00659-18 · Cited by 103
“This molecular system, endorsed by the WHO in 2010 (6), has been demonstrated to be a useful tool for the detection of pulmonary TB (7, 8); however, its sensitivity for extrapulmonary samples remains a challenge due to their low bacillary load (9).”
MethodQuantifying the Burden and Trends of Isoniazid Resistant Tuberculosis, 1994–2009
Jenkins, H. E., Zignol, M., & Cohen, T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022927 · Cited by 103
“In fact, since resistance to rifampin in most settings is usually accompanied by INH-R, some tests that are being used to screen for MDRTB only test for rifampin resistance [28,29].”
BackgroundAccuracy of Tongue Swab Testing Using Xpert MTB-RIF Ultra for Tuberculosis Diagnosis
Andama, A. O., Whitman, G. R., Crowder, R., Reza, T. F., Jaganath, D., Mulondo, J., Nalugwa, T. K., Semitala, F. C., Worodria, W. O., Cook, C. A., et al. (2022) · Journal of Clinical Microbiology · doi:10.1128/jcm.00421-22 · Cited by 101
Pandie, S., Peter, J. G., Kerbelker, Z. S., Meldau, R., Theron, G., Govender, U., Ntsekhe, M., Dheda, K., & Mayosi, B. M. (2014) · BMC Medicine · doi:10.1186/1741-7015-12-101 · Cited by 95
“Preliminary level of detection experiments suggest that the Xpert MTB/RIF assay could reliably detect PF samples spiked with ≥75 cfus/ml of H37Rv, which is lower than the 131 cfu/ml limit of detection found in spiked sputum samples [30].”
MethodSekadde, M. P., Wobudeya, E., Joloba, M. L., Ssengooba, W., Kisembo, H. N., Bakeera‐Kitaka, S., & Musoke, P. (2013) · BMC Infectious Diseases · doi:10.1186/1471-2334-13-133 · Cited by 107
“Studies conducted in the adult population have reported slightly higher sensitivity values of nearly 73% among smear negative culture positive cases [9,10].”
BackgroundMethodNikam, C., Kazi, M. I., Nair, C. B., Jaggannath, M., Manoj, M., Vinaya, R., Shetty, A., & Rodrigues, C. S. (2014) · International Journal of Mycobacteriology · doi:10.1016/j.ijmyco.2014.04.003 · Cited by 101
“Recent studies reported high sensitivity and specificity of the Xpert MTB/ RIF test in the detection of TB from respiratory specimens [5–9], collected from patients living in countries with both high and low prevalence of TB.”
BackgroundDiagnosis and management of miliary tuberculosis: current state and future perspectives
Ray, S., Kundu, S., Sonthalia, N., Talukdar, A., & Khanra (2013) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s29179 · Cited by 92
“When testing a single sputum sample, the assay detects 98%–100% of sputum smear-positive disease and 57%–83% of smear-negative disease among prospectively studied TB suspects.(118) Based on currently available evidence and expert opinion, molecular assays to detect gene mutations that signal drug resistance have been…”
BackgroundRetractedMoure, R., Martín, R., & Alcaide, F. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.06467-11 · Cited by 90
“The Xpert MTB/RIF assay (GX) has been evaluated in detail, and several studies have demonstrated its utility for direct detection in pulmonary specimens (2, 3, 8, 12).”
Yoon, C., Cattamanchi, A., Davis, J. L., Worodria, W. O., den Boon, S., Kalema, N., Katagira, W., Kaswabuli, S., Miller, C. R., Andama, A. O., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048599 · Cited by 97
“[18] Of note, all specimens undergoing Xpert MTB/ RIF testing were expectorated spontaneously.”
MethodSelf-citation
Metadata
- Authors
- Helb, D., Jones, M., Story, E., Boehme, C., Wallace, E., Ho, K., Kop, J., Owens, M. R., Rodgers, R., Banada, P., Safi, H., Blakemore, R., Lan, N. T. N., Jones-López, E. C., Levi, M., Burday, M., Ayakaka, I., Mugerwa, R. D., McMillan, B., Winn-Deen, E., Christel, L., Dailey, P., Perkins, M. D., Persing, D. H., & Alland, D.
- Affiliations
- Rutgers New Jersey Medical School (US)
- Cepheid (United States) (US)
- Department of Medicine, New Jersey Medical School, University of Medicine and Dentistry, New Jersey, Newark, New Jersey
- FIND (CH)
- Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam
- Montefiore Medical Center (US)
- Makerere University (UG)
- ORCID
- Venue
- Journal of Clinical Microbiology
- Publisher
- American Society for Microbiology
- Published
- 2010-01
- Volume
- 48
- Issue
- 1
- Pages
- 229-237
- ISSN
- 0095-1137 (ISSN-L)
- 1098-660X
- PMC
- PMC2812290
- OpenAlex
- W2112022845
- Cited by
- 914
- References
- 59
- Citations by year
- 2026: 29 · 2025: 38 · 2024: 35 · 2023: 33 · 2022: 36 · 2021: 45 · 2020: 65 · 2019: 55 · 2018: 61 · 2017: 62 · 2016: 63 · 2015: 62 · 2014: 74 · 2013: 71 · 2012: 62
- FWCI
- 41.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Journal of Clinical Microbiology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Rutgers University Community Repository (Rutgers University) (submittedVersion)
- Funders
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (R41AI052523, R42AI052523, R42-AI52523, R41-AI52523)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Epidemiology › Mycobacterium research and diagnosis
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Keywords
- Mycobacterium tuberculosis detection, rifampicin resistance, Xpert MTB/RIF, point-of-care testing, real-time PCR, sputum, detection limit, nontuberculous mycobacteria, retreatment tuberculosis, tuberculosis diagnosis
- MeSH terms
- Adolescent, Adult, Aged, Antitubercular Agents, Bacteriological Techniques, Female, Humans, Male, Middle Aged, Mycobacterium tuberculosis, Rifampin, Sensitivity and Specificity, Sputum, Tuberculosis, Uganda, Vietnam, Polymerase Chain Reaction, Point-of-Care Systems, Drug Resistance, Bacterial, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.